Abstracts tagged "interstitial lung disease"

Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Danielle Stahlbaum¹, Renea Jablonski¹, Mary Strek² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
Abstract Number: 1526 • ACR Convergence 2022
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
cosimo bruni¹, Lorenzo Tofani¹, Håvard Fretheim², Sophie Liem³, Arthiha Velauthapillai⁴, Hilde Jenssen Bjørkekjær⁵, Imon Barua², Ilaria Galetti⁶, Alexandru Garaiman⁷, Mike Becker⁷, Anna-Maria Hoffmann-Vold², Jeska de Vries-Bouwstra⁸, Madelon Vonk⁹, Jörg Distler¹⁰, Marco Matucci-Cerinic¹ and Oliver Distler⁷, ¹University of Florence, Florence, Italy, ²Oslo University Hospital, Oslo, Norway, ³LUMC, Leiden, Netherlands, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ⁶Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁰Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement…
Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass¹, Mehdi Nouraie¹, Yingze Zhang¹, Bryant England², Ted Mikuls³, Gail Kerr⁴, Andreas Reimold⁵, Kevin Gibson¹, Marilyn Glassberg⁶, Paul Dellaripa⁷, Tracy Doyle⁷, Chester Oddis⁸ and Dana Ascherman⁸, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵North Texas Veterans Administration Health Care System, Dallas, TX, ⁶Loyola University Chicago Stritch School of Medicine, Chicago, IL, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
Abstract Number: 0050 • ACR Convergence 2022
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Sung Hae Chang¹, Jeongjun Choe², Seon Uk Kim³, Jeong Yeon Kim⁴, Sung Won Lee⁵, Jeong Seok Lee⁶ and Eun Young Lee⁴, ¹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ²Sungkyunkwan University, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University College of Medicine, Seoul, Republic of Korea, ⁵Sooncheonhyang University College of Medicine, Seoul, Republic of Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST, Graduate school of Medical Science and Engineering, Daejeon, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid…
Abstract Number: 0521 • ACR Convergence 2022
Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Lauren Smith¹, Jamie Perin², Adrianne Woods², Fredrick Wigley³, Laura Hummers⁴ and Ami Shah⁵, ¹Johns Hopkins, District Heights, MD, ²John Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins Univerisity, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
Abstract Number: 1109 • ACR Convergence 2022
High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease
Elena Joerns¹, David Karp¹, Jeffrey Sparks², Traci Adams¹, Una Makris³ and Chad Newton¹, ¹UT Southwestern, Dallas, TX, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
Abstract Number: 1527 • ACR Convergence 2022
Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease
Jérôme Avouac¹, Roba Ghossan², Omar Al Tabaa³, Alice Combier², Alexia Steelandt², Marion Thomas⁴ and Yannick Allanore⁵, ¹University of Paris, Paris, France, ²Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ³Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁵Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The benefit of RTX has been suggested for interstitial lung disease (ILD) associated with connective tissue disorders (CTD). Preliminary data have suggested that B…
Abstract Number: 2048 • ACR Convergence 2022
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
Gaetano La Rocca¹, Francesco Ferro², Giovanni Fulvio³, Silvia Fonzetti⁴, Inmaculada Concepción Navarro García⁵, Elena Elefante⁶, Chiara Romei⁷, Marta Mosca⁶ and Chiara Baldini³, ¹University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶University of Pisa, Pisa, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a relatively frequent manifestation of Sjögren's Syndrome (pSS), potentially presenting with a wide spectrum of clinical-radiological characteristics. Anti-Ro52 autoantibodies…
Abstract Number: 0187 • ACR Convergence 2021
Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Vanessa Smith¹, Shervin Assassi², Yannick Allanore³, Lazaro Loaiza⁴, Inga Tschoepe⁵, Madhu Kanakapura⁴ and Elizabeth Volkmann⁶, ¹Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁵Elderbrook Solutions, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁶Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The efficacy and safety of nintedanib have been investigated in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial and in patients with…
Abstract Number: 0413 • ACR Convergence 2021
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
Abstract Number: 1014 • ACR Convergence 2021
Enhanced Expression of Rheumatoid Arthritis Related Autoantibodies Following Airborne Endotoxin Exposure in the Setting of Collagen-Induced Arthritis
Ted Mikuls¹, Rohit Gaurav¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Brianna Shaw¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Carlos Hunter¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In addition to inflammatory arthritis, collagen-induced arthritis (CIA) recapitulates cardinal features of rheumatoid arthritis (RA) including autoreactive T cells, peptidyl-arginine deiminase expression, and citrullination…
Abstract Number: 1683 • ACR Convergence 2021
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Belén Atienza-Mateo¹, Carlos Fernández-Díaz², Santos Castañeda³, Rafael Melero⁴, Francisco Ortiz-Sanjuán⁵, Ivette Casafont⁶, Sebastián C. Rodríguez-García⁷, Iván Ferraz-Amaro⁸, Miguel Ángel gonzalez-Gay⁹ and Ricardo Blanco¹⁰, ¹Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Reina Sofía, Murcia, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁵Hospital Universitario La Fe, Valencia, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ⁷Hospital Universitario Clinic, Barcelona, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe…
Abstract Number: 0188 • ACR Convergence 2021
Effect of Nintedanib on Categorical Changes in FVC in Patients with Progressive Fibrosing ILDs: Further Analyses of the INBUILD Trial
Toby M Maher¹, Stefania Cerri², Robert W Hallowell³, Dirk Koschel⁴, Janet Pope⁵, Leslie Tolle⁶, Heiko Mueller⁷, Klaus B Rohr⁸ and Yoshikazu Inoue⁹, ¹National Heart and Lung Institute, Imperial College London, UK, National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Center for Rare Lung Disease - Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ³Massachusetts General Hospital, Boston, MA, USA, Boston, MA, ⁴Fachkrankenhaus Coswig, Coswig, Germany, Coswig, Germany, ⁵University of Western Ontario, London, ON, Canada, ⁶Department of Pulmonary Medicine and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial in subjects with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of…
Abstract Number: 0430 • ACR Convergence 2021
Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
Brett Doliner¹, Karen Rodriguez¹, Sydney Montesi¹, Xiaoqing Fu¹, Amita Sharma¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: Despite treatment advances, ANCA-associated vasculitis (AAV) remains associated with excess morbidity and mortality. Interstitial lung disease (ILD) is an increasingly recognized manifestation of AAV…
Abstract Number: 1019 • ACR Convergence 2021
Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease
Alyssa Gregory¹, Corrine Kliment¹, Geoffrey Thiele², Michael Duryee², Ted Mikuls², Bryant England², Jill Poole² and Dana Ascherman³, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Cigarette smoking has been epidemiologically linked to the development of ACPA+ rheumatoid arthritis (RA) and, by extension, RA-associated interstitial lung disease (RA-ILD). Providing strong…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].